We chose the EF-1α promoter that confers high levels of transgene expression in iPSCs and NS/PCs, because we plan to use the HSV-TK/GCV system as a safety switch in iPSC-derived NS/PC transplantation for the treatment of spinal cord injury and as a suicide gene therapy for malignant glioma using iPSC-derived NS/PCs. The gene discussed is TKT; the disease is malignant glioma.